Valuation: Cytosorbents Corporation

Market Cap 2.27Cr 1.99Cr 1.84Cr 1.72Cr 3.23Cr 214.43Cr 3.29Cr 22Cr 8.54Cr 105.98Cr 8.54Cr 8.35Cr 367.49Cr P/E 2026 *
-1.96x
P/E 2027 * 12.1x
Enterprise Value 2.27Cr 1.99Cr 1.84Cr 1.72Cr 3.23Cr 214.43Cr 3.29Cr 22Cr 8.54Cr 105.98Cr 8.54Cr 8.35Cr 367.49Cr EV / Sales 2026 *
0.59x
EV / Sales 2027 * 0.48x
Free-Float
84.74%
Yield 2026 *
-
Yield 2027 * -
1 day-21.30%
1 week-17.41%
Current month-26.26%
1 month-26.47%
3 months-38.95%
6 months-46.76%
Current year-43.37%
1 week 0.36
Extreme 0.362
0.52
1 month 0.36
Extreme 0.362
0.6
Current year 0.36
Extreme 0.362
0.84
1 year 0.36
Extreme 0.362
1.3
3 years 0.36
Extreme 0.362
4.29
5 years 0.36
Extreme 0.362
9.8
10 years 0.36
Extreme 0.362
14.95
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2008
Director of Finance/CFO 62 14/08/2024
President 68 28/04/2020
Director TitleAgeSince
Director/Board Member 77 25/07/2011
Director/Board Member 55 01/01/2009
Director/Board Member 65 13/11/2014
Date Insider Type Main position Quantity % Market Cap.
15/06Buy

Chief Financial Officer

1,00,000 0.1592%
15/06Buy

Chief Executive Officer

10,333 0.0165%
18/11Free

Chief Executive Officer

1,00,000 0.1593%
Change 5-day change 1-year change 3-year change Capi.($)
-21.30%-17.41%-70.57%-89.35% 2.27Cr
+1.44%+10.42%+25.66%+0.67% 19TCr
+1.25%-0.51%-24.17%+22.63% 14TCr
+1.75%+10.74%-1.31%-16.09% 14TCr
+0.07%-2.34%-58.48%-17.31% 6.57TCr
+1.18%+3.91%+16.07%+0.65% 5.23TCr
-0.52%-0.03%-27.04%-31.75% 4.35TCr
+0.37%+7.04%+14.13%+16.21% 3.84TCr
-0.66%+5.34%+6.24%+45.27% 3.68TCr
+1.26%+6.77%-11.59%-14.67% 2.99TCr
Average -1.52%+2.27%-13.11%-8.38% 7.4TCr
Weighted average by Cap. +1.04%+5.18%-3.40%+0.67%

Financials

2026 *2027 *
Net sales 3.83Cr 3.35Cr 3.09Cr 2.9Cr 5.43Cr 360.95Cr 5.54Cr 37Cr 14Cr 178.39Cr 14Cr 14Cr 618.57Cr 4.71Cr 4.13Cr 3.81Cr 3.57Cr 6.69Cr 444.52Cr 6.82Cr 46Cr 18Cr 219.69Cr 18Cr 17Cr 761.8Cr
Net income -1.17Cr -1.03Cr -94.89L -88.84L -1.67Cr -110.75Cr -1.7Cr -11Cr -4.41Cr -55Cr -4.41Cr -4.31Cr -189.81Cr 23.73L 20.81L 19.18L 17.96L 33.67L 22Cr 34.37L 2.31Cr 89.2L 11Cr 89.11L 87.16L 38Cr
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26/26/26 $0.3620 -21.30% 3,29,631
25/26/25 $0.4600 -1.50% 54,718
24/26/24 $0.4670 +8.86% 5,80,854
23/26/23 $0.4290 +3.87% 50,517
22/26/22 $0.4130 -5.77% 47,407
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3620USD
Average target price
2.875USD
Spread / Average Target
+694.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock